Claims for Patent: 10,265,287

Summary for Patent: 10,265,287

Title:	Methods of reducing triglycerides and LDL-C
Abstract:	The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.
Inventor(s):	Osterloh; Ian (Kent, GB), Wicker; Pierre (Mystic, CT), Braeckman; Rene (Richboro, PA), Soni; Paresh (Mystic, CT), Manku; Mehar (Birminham, GB)
Assignee:	Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:	15/725,617
Patent Claims:	1. A method of reducing triglycerides and LDL-C in a subject on stable rosuvastatin therapy having baseline fasting triglycerides of 200 mg/dl to about 500 mg/dl comprising, administering daily to the subject for a period of at least about 12 weeks about 4 g of fatty acids composed of at least about 96% ethyl eicosapentaenoate, by weight of all fatty acids, and not more than about 3% docosahexaenoic acid or its esters by weight of all fatty acids, to effect a reduction in triglycerides and LDL-C in the subject. 2. The method of claim 1, wherein the subject has a baseline LDL-C level of about 40 mg/dl to about 115 mg/dl. 3. The method of claim 1, comprising administering said fatty acids to the subject daily for the period to effect a reduction in LDL-C of at least about 10% compared to placebo control. 4. The method of claim 3, comprising administering said fatty acids to the subject daily for the period to effect a reduction in triglycerides of at least about 15% compared to placebo control. 5. The method of claim 1, wherein the fatty acids are administered in 4 capsules, each capsule comprising about 900 mg to about 1.2 g of ethyl eicosapentaenoate. 6. The method of claim 1, wherein the rosuvastatin and at least a portion of the fatty acids are co-administered in different dosage units. 7. A method of reducing triglycerides and LDL-C in a subject on stable rosuvastatin therapy having baseline fasting triglycerides of about 200 mg/dl to about 500 mg/dl comprising, administering to the subject daily for a period of at least about 12 weeks 4 capsules, each capsule comprising about 900 mg to about 1.2 g of ethyl eicosapentaenoate and not more than about 3% docosahexaenoic acid or its esters, by weight of all fatty acids present, to effect a reduction in triglycerides and LDL-C in the subject compared to placebo control. 8. The method of claim 7, comprising administering said capsules to the subject daily for the period to effect a reduction in LDL-C of at least about 10% compared to placebo control. 9. The method of claim 8, comprising administering said capsules to the subject daily for the period to effect a reduction in triglycerides of at least about 15% compared to placebo control. 10. The method of claim 7, wherein each of said 4 capsules comprises about 1 to about 1.1 g of the ethyl eicosapentaenoate. 11. The method of claim 7, wherein the rosuvastatin and ethyl eicosapentaenoate are co-administered in different capsules.